These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25695397)

  • 21. Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.
    Kwak K; Jiang R; Jagu S; Wang JW; Wang C; Christensen ND; Roden RB
    PLoS One; 2013; 8(3):e60507. PubMed ID: 23536912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimized dose of synthetic analogues of Monophosphoryl lipid A as an effective alternative for formulating recombinant human papillomavirus vaccine.
    Azimi A; Heidarian S; Zamani H; Taleghani N; Dehghani M; Seyedjafari E
    Biologicals; 2020 Nov; 68():60-64. PubMed ID: 32859464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years.
    Nelson EA; Lam HS; Choi KC; Ho WC; Fung LW; Cheng FW; Sung RY; Royals M; Chan PK
    Vaccine; 2013 Jul; 31(34):3452-60. PubMed ID: 23770335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines.
    Tsang SH; Basu P; Bender N; Herrero R; Kemp TJ; Kreimer AR; Müller M; Panicker G; Pawlita M; Pinto LA; Sampson JN; Sankaranarayanan R; Schussler J; Sehr P; Sierra MS; Unger ER; Waterboer T; Hildesheim A;
    Vaccine; 2020 Aug; 38(38):5997-6006. PubMed ID: 32713678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and characterization of an HPV18 detection kit using two novel HPV18 type-specific monoclonal antibodies.
    Zhang Y; He Y; Li L; Liang S; Yan M; Ren D; Yang Z; Zhao W; Miao L; Zhang H; Liu Y
    Diagn Pathol; 2018 Aug; 13(1):55. PubMed ID: 30115088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of antibody responses to human papillomavirus vaccination as measured by three assays.
    Robbins HA; Kemp TJ; Porras C; Rodriguez AC; Schiffman M; Wacholder S; Gonzalez P; Schiller J; Lowy D; Poncelet S; Esser M; Matys K; Hildesheim A; Pinto LA; Herrero R; Safaeian M
    Front Oncol; 2014 Jan; 3():328. PubMed ID: 24455487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A nontoxic derivative of lipopolysaccharide increases immune responses to Gardasil HPV vaccine in mice.
    Han JE; Kim HK; Park SA; Lee SJ; Kim HJ; Son GH; Kim YT; Cho YJ; Kim HJ; Lee NG
    Int Immunopharmacol; 2010 Feb; 10(2):169-76. PubMed ID: 19874917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus.
    Robbins HA; Li Y; Porras C; Pawlita M; Ghosh A; Rodriguez AC; Schiffman M; Wacholder S; Kemp TJ; Gonzalez P; Schiller J; Lowy D; Esser M; Matys K; Quint W; van Doorn LJ; Herrero R; Pinto LA; Hildesheim A; Waterboer T; Safaeian M
    BMC Infect Dis; 2014 Mar; 14():120. PubMed ID: 24588945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
    Faust H; Toft L; Sehr P; Müller M; Bonde J; Forslund O; Østergaard L; Tolstrup M; Dillner J
    Vaccine; 2016 Mar; 34(13):1559-1565. PubMed ID: 26896686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second generation of pseudotype-based serum neutralization assay for Nipah virus antibodies: sensitive and high-throughput analysis utilizing secreted alkaline phosphatase.
    Kaku Y; Noguchi A; Marsh GA; Barr JA; Okutani A; Hotta K; Bazartseren B; Fukushi S; Broder CC; Yamada A; Inoue S; Wang LF
    J Virol Methods; 2012 Jan; 179(1):226-32. PubMed ID: 22115786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.
    Bissett SL; Draper E; Myers RE; Godi A; Beddows S
    Vaccine; 2014 Feb; 32(10):1139-46. PubMed ID: 24440205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel® sponges.
    Parker KH; Kemp TJ; Pan Y; Yang Z; Giuliano AR; Pinto LA
    Vaccine; 2018 May; 36(19):2705-2711. PubMed ID: 29631883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurement of the humoral immune response following an incident human papillomavirus type 16 or 18 infection in young women by a pseudovirion-based neutralizing antibody assay.
    Steele J; Collins S; Wen K; Ryan G; Constandinou-Williams C; Woodman CB
    Clin Vaccine Immunol; 2008 Sep; 15(9):1387-90. PubMed ID: 18632924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination.
    Scherpenisse M; Schepp RM; Mollers M; Mooij SH; Meijer CJ; Berbers GA; van der Klis FR
    Clin Vaccine Immunol; 2013 Aug; 20(8):1329-32. PubMed ID: 23740920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.
    Day PM; Pang YY; Kines RC; Thompson CD; Lowy DR; Schiller JT
    Clin Vaccine Immunol; 2012 Jul; 19(7):1075-82. PubMed ID: 22593236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.
    Herrin DM; Coates EE; Costner PJ; Kemp TJ; Nason MC; Saharia KK; Pan Y; Sarwar UN; Holman L; Yamshchikov G; Koup RA; Pang YY; Seder RA; Schiller JT; Graham BS; Pinto LA; Ledgerwood JE
    Hum Vaccin Immunother; 2014; 10(12):3446-54. PubMed ID: 25483691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single serum dilution enzyme-linked immunosorbent assay for determining anti-human papillomavirus (HPV) antibody titres in humans immunised with prophylactic HPV vaccines.
    Jin Y; Kim HJ; Yim GW; Kim YT; Chang DY; Kim HJ
    J Pharm Biomed Anal; 2012 Jul; 66():352-5. PubMed ID: 22469434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.